Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Daito Pharmaceutical Co., Ltd. Buys Back 77,200 Shares for ¥104 million
Source disclosure: March 02, 2026, 15:30 JST
Published by Pulse News Wire: March 02, 2026, 15:32 JST
Daito Pharmaceutical Co.,Ltd. [4577.T]
TOKYO, Mar 02 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) announced progress on its share repurchase program.
The company acquired 77,200 shares for a total of ¥104 million through open market purchases. The board authorized the repurchase of up to 1.00 million shares with a maximum expenditure of ¥1.5 billion.
The program is
Source disclosure: March 02, 2026, 15:30 JST Published by Pulse News Wire: March 02, 2026, 15:32 JST
TOKYO, Mar 02 (Pulse News Wire) – Daito Pharmaceutical Co., Ltd. (4577.T) announced progress on its share repurchase program.
The company acquired 77,200 shares for a total of ¥104 million through open market purchases. The board authorized the repurchase of up to 1.00 million shares with a maximum expenditure of ¥1.5 billion.
The program is 67.4% complete with 674,400 shares acquired to date.